MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Thromboembolism
Interventions
First Posted Date
2007-07-20
Last Posted Date
2019-02-26
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1146
Registration Number
NCT00504556

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

First Posted Date
2007-07-02
Last Posted Date
2015-04-20
Lead Sponsor
Bayer
Target Recruit Count
1280
Registration Number
NCT00494871

Interaction Between ABT-335, Rosuvastatin and Warfarin

First Posted Date
2007-06-15
Last Posted Date
2012-09-28
Lead Sponsor
AstraZeneca
Target Recruit Count
45
Registration Number
NCT00487136
Locations
🇺🇸

Site Ref # / Investigator 5290, Little Rock, Arkansas, United States

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Not Applicable
Conditions
Atrial Fibrillation
Deep Venous Thrombosis
Heart Valve Replacement
Pulmonary Embolism
First Posted Date
2007-06-11
Last Posted Date
2007-06-11
Lead Sponsor
Agency for Healthcare Research and Quality (AHRQ)
Target Recruit Count
260
Registration Number
NCT00484640
Locations
🇺🇸

Marshfield Clinic, Marshfield, Wisconsin, United States

🇺🇸

Third Wave Molecular Diagnostics, Madison, Wisconsin, United States

Anticoagulant Therapy During Pacemaker Implantation

Phase 4
Completed
Conditions
Hemorrhage
Thrombosis
Embolism
Interventions
Device: Permanent pacemaker
Device: Implantable Cardioverter-defibrillator
First Posted Date
2007-05-28
Last Posted Date
2012-09-17
Lead Sponsor
University of Turku
Target Recruit Count
447
Registration Number
NCT00479362
Locations
🇫🇮

Turku University Hospital, Turku, Finland

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2007-03-16
Last Posted Date
2011-12-19
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
448
Registration Number
NCT00448214

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Phase 4
Completed
Conditions
Deep Vein Thrombosis
First Posted Date
2007-02-22
Last Posted Date
2007-02-22
Lead Sponsor
Azienda Ospedaliera Universitaria Policlinico
Target Recruit Count
250
Registration Number
NCT00438230

D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism

Not Applicable
Terminated
Conditions
Venous Thromboembolism
First Posted Date
2007-01-30
Last Posted Date
2011-09-26
Lead Sponsor
Università degli Studi dell'Insubria
Target Recruit Count
73
Registration Number
NCT00428441
Locations
🇮🇹

University Of Insubria, Varese, Italy

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Phase 3
Completed
Conditions
Atrial Fibrillation
Atrial Flutter
Interventions
First Posted Date
2006-12-19
Last Posted Date
2018-07-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20976
Registration Number
NCT00412984
Locations
🇺🇸

David Charles Mishkel, Md, Pa, Boca Raton, Florida, United States

🇺🇸

Heart Care Center, P.C., East Syracuse, New York, United States

🇺🇸

Elkhart Clinic, Llc, Elkhart, Indiana, United States

and more 263 locations

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Phase 1
Completed
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
First Posted Date
2006-11-28
Last Posted Date
2017-08-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
97
Registration Number
NCT00404274
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath